Clinical Trial Update: Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of ibrutinib and lenalidomide in myelodysplastic syndromes has completed. The trial included patients with various MDS …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of California, Davis | Conditions: Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED